Human Vaccines

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

• Study Reliability and Reporting Limitations
• Disclaimers
• Data Interpretation & Reporting Level
• Quantitative Techniques & Analytics
• Product Definitions and Scope of Study
• Prophylactic Vaccines
• Therapeutic Vaccines

II. EXECUTIVE SUMMARY

1. Market Overview & Outlook

• Market Dynamics
• Global Human Vaccine Market: A Snapshot
• Vaccine Pricing: The Developed - Developing Divide
• Overview in the Recent Context
• Historical Perspective
• Successful Vaccine Introductions in the Past
• Looking Ahead
• Key Markets
• Competitive Scenario
• World' s Leading Producers
• Table 1: Leading Players in the Worldwide Human Vaccines Market (2005): Percentage Breakdown by Value Sales for Sanofi-Aventis, GlaxoSmithKline, Wyeth, Merck, and Others (includes corresponding Graph/Chart)
• ALK- The Global Leader in Allergy Vaccines
• Table 2: Leading Players in the Worldwide Allergy Vaccines Market (2005 & 2006): Percentage Breakdown by Value Sales for ALK-Abello, Stallergenes, Allergopharma, and Others (includes corresponding Graph/Chart)

2. Product Overview

• Introduction to the Concept of Immunity
• Role of Vaccines in Strengthening the Immune System
• Vaccines and Immunotherapy
• Historical Overview of Vaccines
• How it Began
• So Far So Good
• Contribution of Animal Research to Vaccine Production
• Types of Vaccines
• Live, Attenuated Vaccines
• Combination Vaccines
• Killed or Inactivated Vaccines
• DNA & Recombinant DNA Vaccines
• Toxoids
• Cellular Fractions
• Conjugate Vaccines
• Subunit Vaccines
• Passive Immunization
• Prophylactic Vaccines
• Prevention Better than Cure
• Prophylactic Pediatric Vaccines
• Vaccination Over the Years
• A Mature Market
• Challenges for Pediatric Vaccines Market
• BCG Vaccine
• Growth Boosting Factors for TB Vaccines
• Demand Restraining Factors for TB Vaccines
• Major Issues to be addressed in the TB Vaccine Market
• Table 3: TB Vaccines Market Worldwide: Annual Sales for 2000-2005 (In US$ Million) (includes corresponding Graph/Chart)
• Hemophilus Influenza Type B Vaccine
• Hib and Combination Vaccines by Producer
• Table 4: Pediatric Haemophilis Influenza B Vaccine Market in the US and Europe: Annual Sales for 2000-2005 (In US$ Million) (includes corresponding Graph/Chart)
• Table 5: Pediatric Haemophilis Influenza B Vaccine Market in the US: Annual Sales for 2000-2005 (In Million Doses) (includes corresponding Graph/Chart)
• Diphtheria/Tetanus/Pertussis Vaccines
• DTP, DTaP, and Combination Vaccines Offered by Major Producers in US
• Table 6: Leading Players in the US DTP and DTaP Vaccines Market (2003-2005): Percentage Breakdown by Value Sales for Sanofi Pasteur, Wyeth, GlaxoSmithkline, and Others (includes corresponding Graph/Chart)
• Table 7: DTP and DTaP Vaccines Market in the US: Annual Sales for 2000-2005 (In US$ Million) (includes corresponding Graph/Chart)
• Table 8: DTP Vaccine Market in Europe: Annual Sales for 2000-2005 (In US$ Million) (includes corresponding Graph/Chart)
• Hepatitis A Vaccine
• Hepatitis B Vaccine
• Hepatitis B Epidemiology
• Table 9: Hepatitis B Vaccines Market in US and Europe: Annual Sales for 2000-2005 (In US$ Million) (includes corresponding Graph/Chart)
• Measles/Mumps/Rubella Vaccines
• Table 10: Measles-Mumps-Rubella (MMR) Vaccine in US and Europe: Annual Sales for 2000-2005 (In US$ Million) (includes corresponding Graph/Chart)
• Table 11: Measles-Mumps-Rubella (MMR) Vaccine Market in the US: Annual Sales for 2000-2005 (In Millions of Doses) (includes corresponding Graph/Chart)
• Rotavirus Vaccines
• Polio Vaccines
• Table 12: Polio Vaccine Market in Europe: Annual Sales for 2000-2005 (In US$ Million) (includes corresponding Graph/Chart)
• Table 13: Polio Vaccines Market in the US: Annual Sales for 2000-2005 (In US$ Million) (includes corresponding Graph/Chart)
• Table 14: Polio Vaccine Market for Both Vaccine Types in the US: Annual Sales for 2000-2005 (In Million Doses) (includes correspondingGraph/Chart)
• Table 15: Polio Vaccine Market for Both Vaccine Types (OPV and IPV) in the US in Percent of Doses from 2000-2005 (includes corresponding Graph/Chart)
• Varicella Vaccine
• Table 16: Varicella Vaccine Market in the US and Europe: Annual Sales for 2000-2005 (In US$ Million) (includes corresponding Graph/Chart)
• Table 17: Varicella Vaccines Market in the US: Annual Sales for 2000-2005 (In Million Doses) (includes corresponding Graph/Chart)
• Need for Combination Vaccines
• Prophylactic Adult Vaccines
• Favorable Market Growth
• Hepatitis A Vaccine
• Hepatitis B Vaccines
• Key Issues Affecting the Adult Hepatitis Vaccines Market
• Cholera Vaccine
• Hepatitis A/Hepatitis B Vaccine
• Japanese Encephalitis Vaccines
• Influenza Vaccines
• Table 18: Global Flu Vaccines Market (2005): Percentage Breakdown by Value Sales for the US, EU, and Rest of the World (includes corresponding Graph/Chart)
• Table 19: Global Flu Vaccines Market (2005): Percentage Breakdown by Volume Sales for Sanofi Pasteur, Chiron, GSK and Others (includes corresponding Graph/Chart)
• Table 20: Rate of Influenza Vaccine Consumption Among Target Groups (includes corresponding Graph/Chart)
• Table 21: Adult Influenza Vaccines Market Worldwide: Annual Sales for 2000-2005 (In US$ Million) (includes corresponding Graph/Chart)
• Growth Boosting Factors for Influenza Vaccines Market
• Key Issues Affecting Influenza Vaccines Market
• Age-Driven Strategies Drive Target Market for Influenza Vaccines
• Healthcare Professionals Increase Target Market for Influenza Vaccines
• Lyme Disease Vaccine
• Pneumococcal Disease Vaccines
• Meningococcal Vaccines
• Rabies Vaccines
• Table 22: Rabies Vaccine Market Worldwide: Annual Sales for 2000-2005 (In US$ Million) (includes corresponding Graph/Chart)
• Typhoid Vaccine
• Yellow Fever Vaccine
• Need for Additional Vaccines
• Therapeutic Vaccines
• DNA Holds the Key
• Huge Potential for Protein Based Vaccines
• Cancer Vaccines
• Human Papillomavirus (HPV) Vaccine
• Breakthroughs in Cancer Vaccine Market
• Factors Affecting the Market for Cancer Vaccines
• Vaccine for AIDS
• What is AIDS?
• Global Statistics
• Table 23: Worldwide HIV/AIDS Estimates - 2007 (includes corresponding Graph/Chart)
• Table 24: Worldwide HIV & AIDS Incidences (2007): A Regional Breakdown for Living and Newly Infected Cases (includes corresponding Graph/Chart)
• Table 25: Worldwide HIV & AIDS Prevalence Rate in Adults Aged between 15 and 49 Years for the Year 2007 (includes corresponding Graph/Chart)
• Asia-Pacific
• Central Asia & Eastern Europe
• Commonwealth of Independent States (CIS)
• Latin America (Including the Caribbean Islands)
• Sub Saharan Africa
• North Africa & the Middle East
• Developed Regions and High Income Countries
• United States
• Table 26: New HIV Infection Cases among Men in the US (2006): Percentage Breakdown by Mode of Infection (includes corresponding Graph/Chart)
• Table 27: New HIV Infection Cases in the US (2006): Percentage Breakdown by Racial/Ethnic Groups (includes corresponding Graph/Chart)
• Table 28: New HIV Infection Cases among Women in the US (2006): Percentage Breakdown by Mode of Infection (includes corresponding Graph/Chart)
• Development of Treatment Options
• Categories of Vaccines for AIDS
• HIV Vaccines in Development
• HIV Vaccines (Prophylactic/Therapeutic) Under Development (2007) by Key Manufacturers
• Malaria Vaccine
• Therapeutic Vaccines Against Infectious Diseases: The Challenges
• Melanoma: Prospects for Treatment
• Vaccines for Melanoma in Development
• Autoimmune Diseases
• How Do Autoimmune Diseases Occur
• Types of Autoimmune Diseases
• Need for Developing Autoimmune Therapeutic Vaccines
• Travel Vaccines: Opportunities
• SARS - Need for Urgent Solutions
• Vaccinations Recommended for Travel to High-Risk Areas
• Mechanisms for Vaccine Delivery
• Edible Vaccines
• Oral Vaccines
• Tablet Based Vaccines
• Mucosal Delivery
• Transdermal Patch Delivery

3. Market Trends & Issues

• Newer Vaccines in Pipeline to Cheer Up Pharma Companies
• Threat of Pandemic Rejuvenates Vaccine Market
• Influenza Vaccines On a Growing Spree
• Influenza Market Faces Several Challenges
• Economic Factors Hamper Optimal Vaccine Development and Delivery
• Increasing Need for Vaccine Promotion in the Developing Regions
• Changing Vaccine Needs
• DNA Vaccines: Engineering Growth
• AIDS Vaccine: Long Road Ahead
• Noninjectable Vaccines: Gain Without Pain
• Need for a Human Vaccine for Leishmaniasis
• Conjugate Vaccines: A Technological Innovation
• Need For a New TB Vaccine
• Companies Involved in TB Vaccine Research
• Religious Concerns Over Immunizing Young Girls
• Changing Travel Patterns Increase Demand for Hepatitis B Vaccine
• DTaP Vaccines Approved for Booster Vaccination
• Advances in Biotechnology Spearheading Vaccines' Growth
• BioWarfare: Threat Perception and Preparedness
• Overview of Potential Bio-Terrorist Agents
• Smallpox (Variola Major)
• Anthrax (Bacillus Anthracis)
• Plague (Yersinia Pestis)
• Botulism (Clostridium Botulinum)
• Tularemia (Francisella Tularensis)
• Market Concerns
• Safety Factor
• Development Delays
• Storage Problems
• Perfluorocarbons as Alternative to Overcome Storage Problems
• Costs
• Standards for Vaccine Safety and Quality

4. Distribution Channels

5. Technological Developments

• Applying Gene Therapy to Develop Therapeutic Solutions
• Research and Trials of AIDS Vaccines
• Ongoing R&D for AIDS Vaccines
• International AIDS Vaccine Initiative (IAVI)
• Cancer
• Cancer Type and Area Effected
• Immunotherapies for Cancer
• Drugs for Cancer
• Issues Effecting the Development of Commercially Viable Cancer Vaccines
• Frequency of Vaccination
• Growth Boosters in the Cancer Vaccines Market
• Cancer Vaccines Available
• Select Cancer Vaccines in Trial Stage
• Other Vaccines for Cancer
• Application of Botulinum Toxin as Delivery Mechanism for Oral Vaccines

6. Clinical Trials

• AVANT' s Single-Dose Oral Ty800 Vaccine Meets Key Endpoints
• Emergent BioSolutions' Typhoid Vaccine Completes Final Phase II Clinical Trial
• Antigenics Announces Positive Data on Phase-I Study of ACAM-FLU-ATM Vaccine
• Bavarian Nordic' s IMVAMUNE® Post-Exposure Vaccination Demonstrates Protection Against Fatal Poxvirus Infection
• BSU Scientists to Commence Human West Nile Vaccine Development Project
• Intercell Concludes First Phase Clinical Studies of IC31® Adjuvanted Influenza Vaccine
• Protherics Commences Phase 2 Angiotensin Vaccine Study
• CSL Biotherapies Files BLA for Influenza Vaccine
• Orchestra Therapeutics Abandons Development of HIV Vaccine
• AlphaVax Concludes Phase I Clinical Trial of Flu Vaccine
• AVANT Presents Preclinical Data on Enteric Vaccine
• Baxter Declares Results of Seasonal Flu Vaccine Candidate Trial
• IDM Pharma Announces Interim Data of Phase II Clinical Trials of Lung Cancer Vaccine
• Novavax Announces Developments in Discovery Program
• Acambis Pioneers Testing of West Nile Virus Vaccine in Grown Ups
• Acambis Initiates Test of single-dose JE vaccine in India
• AVAX Technologies Initiates Phase 3 Clinical Trial For M-Vax
• LigoCyte Pharmaceuticals Begins Clinical Testing of Norovirus Vaccine
• Alphavax Initiates Clinical Testing for Flu and CMV Vaccines
• Sanofi Pasteur Begins Phase 2 Testing of New Influenza Vaccine
• Antigenics Reveals the Preliminary Data of Clinical Trial of Oncophage®
• Baxter Reveals Phase I/II Clinical Trial Results of H5N1 Pandemic Vaccine
• Crucell and AERAS Initiates Tuberculosis Vaccine Clinical Trial
• DOR BioPharma Announces Phase I Results of RiVax™
• GlaxoSmithKline Starts Clinical Trials to Test H5N1 Pandemic Flu Vaccines
• MedImmune Initiates Phase I Clinical Trial of Avian H5N1 Vaccine
• MedImmune Reveals Results of Phase 3 Study for CAIV-T
• MedImmune Initiates Second Phase 1 Study with MEDI-534
• Sanofi Pasteur Initiates First Clinical Trial of Cell Based H7N1 Vaccine
• Therion Biologics Completes Enrollment for Phase III trials of PANVAC-VF
• ViRexx Finishes the Treatment in Phase I Study of HepaVaxx B Vaccine
• Antigenics Begins Phase I Clinical Trial of AG-707
• Positive Results in Novavax' s Pandemic Influenza Vaccine Pre-clinical Trials
• Trials Reveal H5N1 Pre-Pandemic Vaccine of Sanofi Pasteur Effective
• PowderMed Reveals Reveals for Phase 1 Trials for Influenza Vaccine
• Phase II clinical trials of China' s hepatitis B vaccine

7. Research Breakthroughs

• Findings Prove New Nose-Spray Vaccines Effective
• Large Doses of H5N1 Influenza Vaccine Appears Effective
• New Vaccine Technology to Prevent TB
• HPV Vaccine to Help Prevent Cervical Cancer
• Scientists Develop H7N1 Avian Influenza Vaccine
• Human H5N1 Vaccine Developed by Central Hygiene and Epidemiology Institute

8. Product Development

• Nabi Biopharmaceuticals to Develop NicVax Vaccine for Reducing Nicotine Effects
• GenPhar Develops Highly Effective Tetravalent Dengue Vaccine
• Iomai Commences the Development of Prophylactic Traveler™s Diarrhea Vaccine
• Biological Immunological to Produce and Sell r-Hepatitis B Vaccine
• Thailand Researchers Commence the Development of Human Bird Flu Vaccine
• USV to Commercialize Typhoid Vaccine

9. Product Launches

• GlaxoSmithKline to Introduce Five Key Medicines for Oncology
• FFF Enterprises Unveils My Flu Vaccine Network
• ALK-Abello Introduces GRAZAX® Anti-Allergy Vaccine
• Novartis Unveils Influenza Virus Vaccine Fluvirin®
• Wyeth Introduces Latest 7-in-1 Pneumococcal Conjugate Vaccine
• Intervet Releases Arnhem, a Prototype of Avian Influenza Vaccine
• Shantha Launches ' Jencevac' Brain Fever Vaccine
• Wockhardt and Zhejiang Introduces New Hepatitis-A Vaccine
• GSK Introduces Rotarix® Vaccines for Infants
• Sinovac Biotech Introduces Bilive™

10. Recent Industry Activity

• Emergent BioSolutions Acquires Group of Anthrax Monoclonal Antibodies from AVANIR
• China Biopharma and BKXPC Enter into Agreement
• Encorium Signs Contract with Protherics for Phase 2 Trial of ATV for Hypertension
• GenPhar to Establish Vaccine Production Plant in South Carolina
• Intercell Partners SSI and Sanofi Pasteur to Further Develop TB Vaccine
• Intercell and PATH Malaria Vaccine Initiative Form New Partnership for Malaria Vaccine
• Intercell Receives Manufacturer' s License for Production of JE Vaccine
• GSK Receives US FDA Approval for ROTARIX® Rotavirus Vaccine
• Dynavax and Merck & Co Announce Clinical Hold of HEPLISAV Vaccine Trial
• Pharmexa and Ichor Enter into Co-Development Agreement for Multiple DNA Vaccines
• Crucell Enters into Exclusive Development Agreement with Wyeth Pharmaceuticals
• Crucell and Sanofi Ink an Agreement for Advanced Anti-Rabies Biologicals
• FDA Confers Priority Designation for Supplemental Application for GARDASIL ®
• Sanofi Submits a European Marketing Approval Application for First Influenza Vaccine
• IVT Signs an MoU to Take Over Immunotope
• Oxford BioMedica Takes Over Oxxon Therapeutics
• DND Issues RFP for acquisition of MVA-based smallpox vaccine
• GlaxoSmithKline Acquires Reliant Pharmaceuticals
• GSK Acquires Praecis Pharmaceuticals
• Berna Biotech Divests Stake in Pevion Biotech
• GeoVax Signs a Private Placement Agreement with Pure Capital
• Crucell Inks a Research License Agreement with ISU ABXIS of Korea
• China Biopharma Concludes Capital Funding to ZT Biotech
• Crucell and Acambis Ink a Licensing Agreement for PER. C6 ® Technology
• Novartis and Intercell Join Hands to Advance Vaccine Programs
• Serum Institute and Akorn Ink MoU for Vaccine Commercialization in US Market
• Merck Plans to Establish a Human Vaccine Facility in Ireland
• Schering-Plough Acquires Organon Bio Sciences
• Intas Biopharmaceuticals Enters into Collaboration Agreement with Virionics
• Oxxon Therapeutics Starts U.S. Operation
• GenPhar and ImmuneRegen Enter into Research Partnership
• Intercell Submits BLA for JE Vaccine to US FDA
• AVANT and Select Vaccines Enter into R&D Partnership
• AVAX Enters into Agreement with Cancer Treatment Centers of America
• CSC' s DVC and Baxter Receive Contract Modification from U.S. HHS
• DOR BioPharma Enters into CRADA with Walter Reed Army Institute
• Dynavax and Merck to Enter into Partnership to Develop Hepatitis B Vaccine
• Emergent BioSolutions Commences Delivery of BioThrax® to US Health Department
• Maxygen and Sanofi Pasteur sign License Agreement
• Beijing Public Health Bureau Enters into Purchase Agreement with Sinovac
• Novartis Wins US Government Contract for Developing Antigen Technology
• MedImmune Announces Licensing of Reverse Genetics Technology to GlaxoSmithKline
• MedImmune Wins US Government Contract
• MedImmune and Human Genome Sciences Sign Lease Agreement
• Acambis Announces Signing of Collaboration Agreement with Sanofi Pasteur
• Acambis Announces JE Partnership Agreement with Sanofi Pasteur
• Crucell Procures Major Patent for Influenza Vaccine Production
• CSL Receives FDA Approval for Influenza Virus Vaccine
• GlaxoSmithKline Inks Contract with UK Government
• Merck & Co., Inc. and Dynavax to Jointly Develop Hepatitis B Vaccine
• Sanofi Pasteur Wins Contract to Design, Retrofit and Maintain Influenza Vaccine Unit
• Sanofi Pasteur Completes Construction of Influenza Vaccine Production Unit
• Amgen Acquires Abgenix
• Pfizer Acquires PowderMed
• CancerVax and Micromet Merge to Establish Micromet, Inc.
• Novartis Acquires Chiron
• Dynavax Takes Over Rhein Biotech
• AnGes and Vical Ink Collaborative Agreement
• GeoVax Merges with Dauphin
• Hawaii Biotech and Avantogen Merge to Form New Entity
• CytoDyn Acquires Advanced Influenza Technologies
• Emergent BioSolutions Acquires VIVACS
• Acambis Divests Berna Business to Crucell
• Novavax Inks an Agreement with Bharat Biotech to Develop Avian Flu Vaccine
• Aeras Receives License for Developing and Distributing Tuberculosis Vaccine
• Acambis to Supply Smallpox Vaccine to CDCP
• AlphaVax and Wyeth Enhance Existing Licensing Agreement
• Baxter Enters into a Contract to Supply Pandemic Influenza Vaccine
• Sanofi Pasteur Signs Stockpile Contract with the US Government
• Crucell Licenses PER.C6® Technology to ADImmune Corporation
• Baxter Wins Stockpile Production Contract for H5N1 from the NHS
• Crucell Earns NIH Contract to Develop HIV Vaccine
• Novartis Secures Stockpile Supply Contract from the US Government
• Novartis Signs Distribution Agreement with Intercell
• GSK Receives Stockpile Supply Contract for Fly Pandemic from the HHS
• GSK Signs H5N1 Antigen Influenza Vaccine Contract with Switzerland
• DOR BioPharma Forms Alliance to Develop Ricin Vaccine
• Nobilon and NVI to Jointly Develop RSV Vaccine
• SciGen and OctoPlus Join Forces to Develop Hepatitis B Vaccine Delivery
• AlphaVax Receives Patent for Alphavaccines Manufacturing Process
• IVI Receives Funds for Cholera Vaccine Development Program
• Novavax Forms Strategic Alliance with US-based, PacificGMP
• Sanofi Pasteur Enters into Partnership with PDVI
• MedImmune Inks a Cooperative R&D Agreement with NIAID
• MedImmune Bags a Five-Year HHS Contract
• Novavax Enters into a Cooperative Research Agreement with CDC
• GlaxoSmithKline Establishes New Vaccine Manufacturing Facility
• GenPhar Extends R&D Contract with NMRC
• Medlmmune Files for INDA with FDA for a New Influenza Vaccine
• Rotarix™ Vaccines Receives European Approval
• Merck' s GARDASIL® Receives FDA Approval
• CDC Adds Merck' s GARDASIL® Under its VFC Category in the US
• Medlmmune Submits sBLA to the FDA Refrigerator-Stable Influenza Vaccine
• Medlmmune Submits sBLA to the FDA for Expanded Label for CAIV-T
• Medlmmune Receives FDA Approval for the Use of Reverse Genetics Technology
• Vivalis Starts a New Plant in France to Produce Viral Vaccines
• Fiocruz Provides Yellow-Fever Vaccine to Peruvian Government
• Merck Receives FDA Approval for Zostavax Vaccine
• The US Health and Human Services Department Awards Grant to Pharma Companies
• GlaxoSmithKline Expands License and Supply Agreement with Antigenics
• GlaxoSmithKline Applies for Approval for Cervical Cancer Vaccine
• Omnia Biologics Signs Deal with Aeras Global TB Vaccine Foundation
• Aeras Alliances with Dutch Scientific Organizations to Develop Latest TB Vaccines
• Embrex, Shenzhen, and P.R. China Team Up for Manufacturing Influenza Vaccine
• Health Canada Grants Approval to Merck' s RotaTeq
• HepaLife Technologies Receives License for Technology from MSU
• Hindustan Latex Ties-up with Bharat Biotech for Marketing Vaccines
• Emergent BioSolutions and Sanofi Pasteur Sign Agreement
• USV and BCIL Enter into Agreement
• GenVec Receives Fifth-Year Extension of Contract from NIAID
• Inovio Joins Hands with Tripep to Develop Hepatitis C Vaccine
• Novavax and Bharat Biotech Form Alliance to Develop Pandemic Flu Vaccine
• Panacea Biotech Joins Hands with NVI to Create Polio Vaccine
• Immune Response Ties Up with Accelsiors for Trial of NeuroVax Vaccine
• Nordic Vaccine Joins Forces with Ace BioSciences to Develop Efficient Vaccines
• Eisai Partners with DNAVEC to Develop New Vaccine
• ViRexx Partners with DRDC to Develop Biodefence Vaccines
• Biovirx Teams Up with IDT to Reintroduce Vaccine for Infants
• LG Life Sciences Enters into Agreement with Sinovac
• MediGene Awards Licenses to Virionics for CVLP Vaccine Program
• FluLaval Influenza Vaccine Receives FDA Approval
• Merck Applies for Approval to Market Gardasil in China
• Bio-Bridge Establishes New Vaccine Facility in China
• SIIL Established the First-ever Biotech SEZ in India
• Aeras Foundation Establishes New Laboratory for TB Vaccine
• China Biopharma Distributes Flu Vaccine in China
• ViroPro Founds New Subsidiary for Developing Medicinal Vaccines
• Glaxosmithkline Acquires Corixa Corporation
• GSK Acquires ID Biomedical
• Pharmexa Acquires GemVax

11. Focus on Select Global Players

• ALK - Abello A/S (Denmark)
• Acambis PLC (UK)
• Bavarian Nordic A/S (Denmark)
• Crucell N.V. (The Netherlands)
• CSL Ltd. (Australia)
• GlaxoSmithKline PLC (UK)
• GlaxoSmithKline Biologicals S.A (Belgium)
• Medimmune, Inc. (USA)
• Merck & Company, Inc. (USA)
• Novartis Vaccines & Diagnostics, Inc. (USA)
• Sanofi-Aventis S A (France)
• Sanofi-Pasteur SA (France)
• Sanofi Pasteur Inc. (USA)
• Shantha Biotechnics Ltd. (India)
• Vaxin, Inc. (USA)
• Wyeth (USA)

12. Global Market Perspective

• Table 29: World Recent Past, Current & Future Analysis for Human Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)
• Table 30: World Long-term Projections for Human Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 31: World Historic Market Review for Human Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart)
• Table 32: World 10-Year Perspective for Human Vaccines by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 33: World Recent Past, Current & Future Analysis for Prophylactic Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)
• Table 34: World Long-term Projections for Prophylactic Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 35: World 10-Year Perspective for Prophylactic Vaccines by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 36: World Recent Past, Current & Future Analysis for Prophylactic Vaccines by Product Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)
• Table 37: World Long-term Projections for Prophylactic Vaccines by Product Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 38: World 10-Year Perspective for Prophylactic Vaccines by Product Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2003, 2008 & 2012
• Table 39: World Recent Past, Current & Future Analysis for Pediatric Prophylactic Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)
• Table 40: World Long-term Projections for Pediatric Prophylactic Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 41: World 10-Year Perspective for Pediatric Prophylactic Vaccines by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 42: World Recent Past, Current & Future Analysis for Adult Prophylactic Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)
• Table 43: World Long-term Projections for Adult Prophylactic Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 44: World 10-Year Perspective for Adult Prophylactic Vaccines by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 45: World, Recent Past, Current & Future Analysis for Therapeutic Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)
• Table 46: World Long-term Projections for Therapeutic Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 47: World 10-Year Perspective for Therapeutic Vaccines by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)

III. MARKET

1. The United States

• A. Market Analysis
  • Outlook
  • Current & Future Analysis
  • Market Constraints
  • Supply Shortages
  • Pediatric Vaccines Market
  • Market Focus Shifting From Pediatric Vaccines
  • Growth Boosting Factors for US Pediatric Vaccines Market
  • Demand Restraining factors for US Pediatric Vaccines Market
  • Table 48: Pediatric Vaccine Market in the US: Annual Sales for 2000-2005 (In Millions of Doses) (includes corresponding Graph/Chart)
  • Table 49: US Pediatric Vaccine Market: Percent of Doses by Vaccine Type - 2000 through 2005 (includes corresponding Graph/Chart)
  • ' Bright' Outlook for Therapeutic Vaccines
  • Select Cancer Vaccines in Pipeline in the US
  • Market Share of Key Players in North America
  • Table 50: Leading Players in the North American Human Vaccines Market (2005): Percentage Breakdown by Value Sales for Merck, Sanofi-Aventis, Wyeth, GlaxoSmithKline, and Others (includes corresponding Graph/Chart)
  • The US Influenza Vaccine Market
  • Table 51: The US Seasonal Influenza Vaccine Market - Production and Distribution of Influenza Vaccine in Million Units (includes corresponding Graph/Chart)
  • Table 52: Funds Forwarded by HHS for Influenza Vaccine Production (2005-2006) to Key Vaccine Manufacturers (In US Dollars) (includes corresponding Graph/Chart)
  • Influenza Vaccine Producers for the 2006-2007 Influenza Season
  • Problems Effecting Timely Supply of Influenza Vaccine
  • Table 53: Influenza Vaccines Market in the US (2005): Percentage Breakdown of Value Sales for Sanofi Aventis, Chiron, GSK, and Medimmune (includes corresponding Graph/Chart)
  • Key Statistics
  • Table 54: Number of Children Under 5 Years of Age in the US (In Millions) (includes corresponding Graph/Chart)
  • Vaccines and Intended User Group
  • Need for Immunization Schedule for Adults
  • Federal Research and Grants
  • National Cancer Institute
  • National Institutes of Health (NIH)
  • NIH Scientists Showcase Potential West Nile Virus Vaccine
  • NIH Doles Out Grants to Biotech Companies
  • Development Funds for HIV Vaccines
  • Development Funds for Biodefense-Related Vaccines
  • The National Institute of Allergy and Infectious Diseases (NIAID)
  • Intramural Research
  • Extramural Divisions
  • Vaccine Pricing in the US
  • Table 55: The US Vaccine Market: Vaccine Prices in US$ Per Dose (2002-2005) (includes corresponding Graph/Chart)
  • Regulatory Environment
  • Review Process Make Vaccines Safer
  • Imports-Exports Scenario in the Recent Past
  • Exports of Human Vaccines for 2004
  • Table 56: US Domestic Exports of Vaccines for Human Medicine for the Year 2004 (Value in ' 000 US Dollars) (includes corresponding Graph/Chart)
  • Imports of Human Vaccines for 2004
  • Table 57: US Imports of Vaccines for Human Medicine for the Year 2004 (Value in ' 000 US Dollars) (includes corresponding Graph/Chart)
  • Clinical Trials
  • Product Developments
  • Strategic Corporate Developments
  • Select Players
  • Alphavax Inc.
  • Antigenics Inc.
  • Avax Technologies, Inc.
  • Avant Immunotherapeutics, Inc.
  • Baxter International Inc.
  • Cell Genesys Inc.
  • Dendreon Corporation
  • DOR Biopharma Inc.
  • Dynavax Technologies Corp.
  • Emergent BioSolutions Inc.
  • GenPhar, Inc.
  • IDM Pharma, Inc
  • ImClone Systems, Inc.
  • Ligocyte Pharmaceuticals, Inc
  • Maxygen, Inc.
  • MedImmune, Inc
  • Merck & Company, Inc
  • Micromet, Inc.
  • Novartis Vaccines & Diagnostics, Inc.
  • Novavax, Inc.
  • Orchestra Therapeutics, Inc.
  • Progenics Pharmaceuticals Inc. .
  • Sanofi Pasteur Inc.
  • Vaxin, Inc.
  • Wyeth
• B. Market Analytics
  • Table 58: US Recent Past, Current & Future Analysis for Human Vaccines by Product Group/Segment - Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)
  • Table 59: US Long-term Projections for Human Vaccines by Product Group/Segment - Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 60: US Historic Review for Human Vaccines - Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart)
  • Table 61: US 10-Year Perspective for Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

2. Canada

• A. Market Analysis
  • Clinical Trial
  • Strategic Corporate Developments
• B. Market Analytics
  • Table 62: Canadian Recent Past, Current & Future Analysis for Human Vaccines by Product Group / Segment - Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)
  • Table 63: Canadian Long-term Projections for Human Vaccines by Product Group/Segment - Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 64: Canadian Historic Review for Human Vaccines - Annual Sales Figures in US$$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart)
  • Table 65: Canadian 10-Year Perspective for Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

3. Japan

• A. Market Analysis
  • Strategic Corporate Development
• B. Market Analytics
  • Table 66: Japanese Recent Past, Current & Future Analysis for Human Vaccines by Product Group/ Segment - Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)
  • Table 67: Japanese Long-term Projections for Human Vaccines by Product Group/Segment - Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 68: Japanese Historic Review for Human Vaccines - Annual Sales Figures in US$$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart)
  • Table 69: Japanese 10-Year Perspective for Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4. Europe

• A. Market Analysis
  • Vaccine Pricing in Europe
  • Major Drawbacks
  • Current & Future Analysis
  • Regulatory Mechanism for Vaccines in Europe
  • Select Players
  • Table 70: Leading Players in the European Human Vaccines Market (2005): Percentage Breakdown by Value Sales for GlaxoSmithKline & Sanofi Pasteur, Wyeth, and Others (includes corresponding Graph/Chart)
  • Table 71: Influenza Vaccines Market in Europe (2005 & 2006): Percentage Breakdown of Value Sales for Sanofi Pasteur, GSK, Novartis Vaccines, and Others in US$ Million (includes corresponding Graph/Chart)
  • Strategic Corporate Developments
• B. Market Analytics
  • Table 72: European Recent Past, Current & Future Analysis for Human Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)
  • Table 73: European Long-term Projections for Human Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 74: European Historic Review for Human Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia & Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart)
  • Table 75: European 10-Year Perspective for Human Vaccines by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
  • Table 76: European Recent Past, Current & Future Analysis for Human Vaccines by Product Group/Segment - Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)
  • Table 77: European Long-term Projections for Human Vaccines by Product Group/Segment - Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 78: European 10-Year Perspective for Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4a. France

• A. Market Analysis
  • Clinical Trials
  • Strategic Corporate Developments
  • Select Players
  • Sanofi-Aventis
  • Sanofi Pasteur SA
• B. Market Analytics
  • Table 79: French Recent Past, Current & Future Analysis for Human Vaccines by Product Group/Segment - Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)
  • Table 80: French Long-term Projections for Human Vaccines by Product Group/Segment - Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 81: French Historic Review for Human Vaccines - Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart)
  • Table 82: French 10-Year Perspective for Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4b. Germany

• A. Market Analysis
  • Merck KgaA - A Major Player
  • Product Launch
  • Strategic Corporate Development
• B. Market Analytics
  • Table 83: Germany Recent Past, Current & Future Analysis for Human Vaccines by Product Group/Segment - Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)
  • Table 84: Germany Long-term Projections for Human Vaccines by Product Group/Segment - Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 85: German Historic Review for Human Vaccines - Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart)
  • Table 86: German 10-Year Perspective for Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4c. Italy

• Market Analysis
• Table 87: Italian Recent Past, Current & Future Analysis for Human Vaccines by Product Group/Segment - Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)
• Table 88: Italian Long-term Projections for Human Vaccines by Product Group/Segment - Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 89: Italian Historic Review for Human Vaccines - Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart)
• Table 90: Italian 10-Year Perspective for Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4d. The United Kingdom

• A. Market Analysis
  • The UK Vaccine Industry Group (UVIG)
  • Clinical Trial
  • Product Development
  • Strategic Corporate Developments
  • Select Players
  • Acambis PLC
  • BioVex
  • GlaxoSmithkline PLC
  • Oxford Biomedica PLC
• B. Market Analytics
  • Table 91: UK Recent Past, Current & Future Analysis for Human Vaccines by Product Group/Segment - Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)
  • Table 92: UK Long-term Projections for Human Vaccines by Product Group/Segment - Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 93: UK Historic Review for Human Vaccines - Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart)
  • Table 94: UK 10-Year Perspective for Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4e. Spain

• Market Analysis
• Table 95: Spanish Recent Past, Current & Future Analysis for Human Vaccines by Product Group/Segment - Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)
• Table 96: Spanish Long-term Projections for Human Vaccines by Product Group/Segment - Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 97: Spanish Historic Review for Human Vaccines - Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart)
• Table 98: Spanish 10-Year Perspective for Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4f. Russia

• Market Analysis
• Table 99: Russian Recent Past, Current & Future Analysis for Human Vaccines by Product Group/Segment - Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)
• Table 100: Russian Long-term Projections for Human Vaccines by Product Group/Segment - Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 101: Russian Historic Review for Human Vaccines - Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart)
• Table 102: Russian 10-Year Perspective for Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4g. Rest of Europe

• A. Market Analysis
  • Pediatric Vaccines Generate High Sales
  • Clinical Trials
  • Strategic Corporate Developments
  • Select Players
  • ALK - Abello A/S (Denmark)
  • Bavarian Nordic A/S (Denmark)
  • Crucell N.V. (The Netherlands)
  • GlaxoSmithKline Biologicals S.A (Belgium)
  • Innogenetics NV (Belgium)
  • Intercell AG (Austria)
  • Pharmexa A/S (Denmark)
• B. Market Analytics
  • Table 103: Rest of Europe Recent Past, Current & Future Analysis for Human Vaccines by Product Group/Segment - Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)
  • Table 104: Rest of Europe Long-term Projections for Human Vaccines by Product Group/Segment - Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 105: Rest of Europe Historic Review for Human Vaccines - Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart)
  • Table 106: Rest of Europe 10-Year Perspective for Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

5. Asia-Pacific

• A. Market Analysis
  • Asian Vaccine Industry
  • Challenges
  • China
  • State Drug Administration: Regulatory Authority in China
  • India
  • Development Pipeline
  • Hepatitis B Vaccine in India
  • Hepatitis B Vaccines in India
  • Panacea Biotec: A Leading Manufacturer of Hepatitis B Vaccine
  • Combination Vaccines
  • Indian Vaccine Market - Combination Vaccines Available in the Country
  • Indian Vaccine Market - New Combination Vaccines Under Development by Major Companies
  • International Players Entering the Arena
  • Major Partnerships Between Indian and International Players
  • Heading Towards Greener Pastures
  • The Patent Act (Third Amendment), 2005
  • Clinical Trials
  • Product Developments
  • Strategic Corporate Developments
  • Select Players
  • CSL Ltd. (Australia)
  • GreenCross Vaccine Co., Ltd. (South Korea)
  • Human Biologicals Institute (India)
  • Serum Institute of India, Ltd. (India)
  • Shantha Biotechnics Ltd. (India)
  • Sinovac Biotech Co. Ltd. (China)
  • Wockhardt Limited (India)
• B. Market Analytics
  • Table 107: Asia-Pacific Recent Past, Current & Future Analysis for Human Vaccines by Product Group/Segment - Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)
  • Table 108: Asia-Pacific Historic Review for Human Vaccines - Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart)
  • Table 109: Asia-Pacific Long-term Projections for Human Vaccines by Product Group/Segment - Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 110: Asia-Pacific 10-Year Perspective for Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

6. Latin America

• A. Market Analysis
  • Need for an effective TB Vaccine in Brazil
  • Product Launch
  • Strategic Corporate Development
• B. Market Analytics
  • Table 111: Latin America Recent Past, Current & Future Analysis for Human Vaccines by Product Group/Segment - Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)
  • Table 112: Latin America Long-term Projections for Human Vaccines by Product Group/Segment - Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 113: Latin America Historic Review for Human Vaccines - Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart)
  • Table 114: Latin American 10-Year Perspective for Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets for2003, 2008 & 2012 (includes corresponding Graph/Chart)

7. Rest of World

• Market Analysis
• Table 115: Rest of World Recent Past, Current & Future Analysis for Human Vaccines by Product Group/Segment - Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)
• Table 116: Rest of World Long-term Projections for Human Vaccines by Product Group/Segment - Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 117: Rest of World Review for Human Vaccines - Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart)
• Table 118: Rest of World 10-Year Perspective for Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

COMPETITIVE LANDSCAPE